Rashid Sayyid converses with Dr. Neil Fleshner about the outcomes of the MAST trial, which examined the effects of metformin on patients under active surveillance for prostate cancer. Despite promising preclinical evidence suggesting metformin’s potential benefits against prostate cancer, the trial results were unexpectedly negative, showing no significant advantage of metformin in preventing…
Andrea Miyahira interviews Cornelia (Chien-Kuang) Ding about her study on predicting prostate cancer grade reclassification using a deep learning-based grading algorithm. Dr. Ding discusses their…
David McConkey discusses the application of artificial intelligence (AI) in bladder cancer research, focusing on AI pathology. He outlines ongoing collaborations between cooperative groups and…
Ashish Kamat introduces Armine Smith to discuss the intricacies of treating female bladder cancer, emphasizing organ and sexual function preservation during radical cystectomy. Highlighting a…
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Daniel Kwon presents a study on genetic counseling for Veterans with advanced prostate cancer. This mixed-methods research combines in-depth qualitative interviews and quantitative surveys to…
Novo Nordisk’s next-generation obesity candidate led to substantial weight loss in a pivotal study but fell short of expectations
In this episode, we’re joined by Dr. Piraye Yurttas Beim, founder and CEO of Celmatix, a women’s health biotech company. She discusses the funding the…
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies:…
Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the end of January.
